Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 7/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.49 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1101337 | 0.82 | KDM4E (0.68) | FKBP1AL3MBTL1TSHRUSP2POLB | |
| SCHEMBL31428561 | 0.78 | FKBP1A (0.57) | FKBP1AL3MBTL1TSHRUSP2POLB | |
| SCHEMBL12988518 | 0.77 | FKBP1A (0.71) | FKBP1AL3MBTL1TSHRPOLBALDH1A1 | |
| SCHEMBL12169303 | 0.76 | FKBP1A (0.69) | FKBP1AL3MBTL1TSHRPOLBALDH1A1 | |
| SCHEMBL31428775 | 0.76 | FKBP1A (0.69) | FKBP1AL3MBTL1TSHRUSP2POLB | |
| SCHEMBL6631915 | 0.76 | FKBP1A (0.69) | FKBP1AL3MBTL1TSHRPOLBALDH1A1 | |
| SCHEMBL13917218 | 0.75 | FKBP1A (0.64) | FKBP1AL3MBTL1TSHRPOLBALDH1A1 | |
| SCHEMBL31428914 | 0.75 | FKBP1A (0.61) | FKBP1AUSP2POLBALDH1A1KDM4E | |
| SCHEMBL7316803 | 0.75 | FKBP1A (0.67) | FKBP1AL3MBTL1TSHRPOLBALDH1A1 | |
| SCHEMBL12015661 | 0.74 | FKBP1A (0.66) | FKBP1AL3MBTL1TSHRUSP2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2025-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | BRAF, RAF1, NRAS | FKBP1A 2064/4885L3MBTL1 1560/4885TSHR 1389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.